

# Parallel Session 2

## Non-Threshold Carcinogens

# **1. Identification of methodologies and approaches**

*Valid documentations are available:*

- Risk assessment methodologies & approaches by SCHER, SCCP, SCENIHR (prelim. Report of 24. Oct. 2008)
- IPCS Mode-of Action Framework (different publications)

## 2. Particular relevant problems

- The threshold concept is generally accepted for nongenotoxic carcinogens and is plausible for certain genotoxic carcinogens
- Carcinogenicity, especially quantitative, generally cannot be predicted based on in vivo data only. They may point to hazard only. Importance of toxicokinetics.
- Dose selection problems important!
- The WoE (weight of evidence) -> MoE approach appears appropriate. But how large should the MoE be?
- BMD / T-25 calculations again depend on the quality of data; they can be used if quantitative data are needed.
- The current classification system is only hazard-based. This is not the scientific state of the art.

### 3. Identify best practices

- There are guidance procedures from EFSA, JECFA, IPCS, EPA that can be used.
- Exposure assessment is frequently the weak point (-> other workgroup).
- Case study developments should be enforced.

#### **4. Recommendations to improve practices**

- We need an inventory/repository of existing case studies (include- MoA and regulatory status).
- Research in the MoA area should be internationally supported as to contribute to the development of case studies
- The translation of scientific findings into regulation is inadequate and thus necessary

## **5. Recommendations to be followed up**

- The present hazard-based classification system should be re-evaluated to incorporate elements of risk, to the extent possible.
  - Integrate existing elements (such as of EPA, national bodies, SCOEL).
  - A task group should be committed with developing a white paper.
  - Continue a global dialogue, as also GHS is to be addressed.

**This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.**